05:09 AM
Health-care giant Baxter International (BAX) might be just the cure for investors sick of anemic returns, writes Barron's Sandra Ward. The company delivered double-digit earnings growth last year and is expected to repeat the performance this year.
2 Comments
Friday, January 23, 2009
10:39 AM
After years of focusing on organic growth, Baxter (BAX) says it's considering outside deals: "It may be a more target-rich environment right now," CEO Robert Parkinson says on call. While not losing sight of margin expansion, he sees the chance to "be a bit more expansive in evaluating opportunities and perhaps bringing things in."
Comment!
Thursday, January 22, 2009
07:14 AMBaxter International (BAX): Q4 EPS of $0.91 beats by $0.02. Revenue of $3.13B (+4.1%) vs. $3.15B. (PR)
Comment!
07:21 AMBaxter (BAX): Q3 EPS of $0.88 beats by $0.06. Revenue of $3.15B (+14.6%) in-line. Cash flow from operations $1.9B up from $1.6B Y/Y. "The medically-necessary nature of our product offering, our diversified portfolio and global presence, and our financial strength and flexibility, provide us with a solid foundation in this uncertain global economy." [PR]
Comment!
08:28 AM
Baxter (BAX): Q2 EPS of $0.85 beats by $0.03. Revenue of $3.2B vs. consensus $3.05B. Raises full-year EPS guidance to $3.28-3.32 from $3.18-3.24 vs. consensus $3.24. Shares -0.3%. [PR]
Comment!